- Research works
- 13 ▼ 68% vs 2013–17
- Citations
- 261 20.7 per fractional work
- Top-10% rate
- 20.0% record average 16.5%
- Open access
- 45% world 28%
Not ranked overall: CytoCure (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does CytoCure (United States) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, T-cell and B-cell Immunology, Advanced Biosensing Techniques and Applications and Monoclonal and Polyclonal Antibodies Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 1 works
- 2 T-cell and B-cell Immunology Immunology 1 works
- 3 Advanced Biosensing Techniques and Applications Molecular Biology 1 works
- 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 5 Immunodeficiency and Autoimmune Disorders Immunology 0 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has CytoCure (United States)'s research output changed?
Output in 2018–2022 was 68% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Beverly
- Clinical Solutions
- Beverly Hospital
- Wound Healing Society
- School for Field Studies
- American Association for Thoracic Surgery
- Axcelis Technologies (United States)
- CCI Reprographics (United States)
- Rogers Sciences (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.